 The FDA has signed off Vaxart Incs NASDAQ: VXRT Investigational New Drug application for an S-only oral tablet SARS-CoV-2 vaccine candidate. This is great news because it allows us to move forward with our first S-only vaccine construct, said Andrei Floroiu, Vaxarts Chief Executive Officer. 